Description
Copegus Coated Tablets 200 mg. №168
Ingredients:
Each coated tablet contains 200 mg of Ribavirin.
Mechanism of Action:
Ribavirin, the active ingredient in Copegus, exerts its antiviral effects by inhibiting the replication of RNA and DNA viruses, including the hepatitis C virus. It disrupts viral RNA synthesis and viral mRNA capping, ultimately suppressing viral replication.
Pharmacological Properties:
Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity. It is phosphorylated intracellularly to form active nucleoside triphosphates that interfere with viral replication. Additionally, Ribavirin modulates the host immune response to enhance viral clearance.
Indications for Use:
Copegus is indicated for the treatment of chronic hepatitis C in combination with pegylated interferon alfa and other antiviral agents in adults.
Contraindications:
Do not use Copegus if you are pregnant, breastfeeding, have autoimmune hepatitis, severe renal impairment, hemoglobinopathies, or co-administration with didanosine. Use with caution in patients with cardiac disease, hepatic dysfunction, and psychiatric disorders.
Side Effects:
Common side effects of Copegus include fatigue, anemia, insomnia, depression, and flu-like symptoms. Serious adverse reactions may include hemolytic anemia, pulmonary disorders, and birth defects. Close monitoring is essential during treatment.
Usage Instructions:
The dosage of Copegus is individualized based on body weight and medical history. It is typically administered orally with food. Consult your healthcare provider for the precise dosing regimen and duration of treatment.
Benefits Compared to Analogues:
Copegus, in combination therapy, has demonstrated superior efficacy in achieving sustained virologic response and preventing disease progression compared to monotherapy or older interferon-based regimens. Its tolerability profile and convenience contribute to better treatment adherence.
Suitable Patient Groups:
Copegus is suitable for adult patients with chronic hepatitis C who have not undergone previous treatment or who have relapsed after initial therapy. Special considerations are required for pediatric patients, elderly individuals, and those with comorbidities; dosing adjustments may be necessary.
Storage and Shelf Life:
- Store Copegus at room temperature (20-25°C) in a dry place away from direct sunlight and moisture.
- Do not use the medication beyond the expiration date printed on the packaging.
Packaging Description:
Copegus is available as coated tablets in a pack size of 168 tablets. Each tablet is film-coated for oral administration, ensuring accurate dosing and protection from environmental factors.
Clinical Evidence and Proven Effectiveness:
Ribavirin, in combination therapy, has been extensively studied in clinical trials for its efficacy in chronic hepatitis C treatment. Studies have shown that Ribavirin-based regimens significantly improve sustained virologic response rates, leading to viral clearance and histological improvement.
